Sagent Pharmaceuticals - FDA Approval of Clindamycin Injection

Welcome to CRWENewswire, Stocks to watch. I am Sara Bryant. Sagent Pharmaceuticals Incorporated - symbol SGNT - reported FDA approval of Clindamycin Injection, USP, an antibiotic used to treat bacterial infections. Sagent’s latex-free clindamycin will be available in three single-dose vial sizes and in pharmacy bulk packaging. The company expects to launch the product in early 2012. According to IMS, the 2011 U.S. market for injectable clindamycin approximates $65 million. Sagent Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Thank you for joining me and stay with us! For CRWE Newswire, Stocks to Watch, I’m Sara Bryant

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

1. By: karmastock
2. Categories News & Events
3. Views 79
4. Added :01-Oct-11
   Report This Video